PDF herunterladen
Semin Thromb Hemost 2013; 39(06): 585-595
DOI: 10.1055/s-0033-1349222
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Congenital Fibrinogen Disorders: An Update

Philippe de Moerloose
1   Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland
,
Alessandro Casini
2   Division of Haematology, University Hospital, Geneva, Switzerland
,
Marguerite Neerman-Arbez
3   Department of Genetic Medicine and Development, University Medical School, Geneva, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. Juli 2013 (online)

   Lizenzen und Reprints

Abstract

Hereditary fibrinogen abnormalities comprise two classes of plasma fibrinogen defects: Type I, afibrinogenemia or hypofibrinogenemia, which has absent or low plasma fibrinogen antigen levels (quantitative fibrinogen deficiencies), and Type II, dysfibrinogenemia or hypodysfibrinogenemia, which shows normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies). In afibrinogenemia and hypofibrinogenemia, most mutations of the FGA, FGB, or FGG fibrinogen encoding genes are null mutations. In some cases, missense or late truncating nonsense mutations allow synthesis of the corresponding fibrinogen chain but intracellular fibrinogen assembly and/or secretion are impaired. Afibrinogenemia is associated with mild-to-severe bleeding, whereas hypofibrinogenemia is most often asymptomatic. Thromboembolism may occur either spontaneously or in association with fibrinogen substitution therapy. Women with afibrinogenemia suffer from recurrent pregnancy loss but this can also occur in women with hypofibrinogenemia. Dysfibrinogenemia, caused mainly by missense mutations, is commonly associated with bleeding, thrombophilia, or both; however, most individuals are asymptomatic. Hypodysfibrinogenemia is a subcategory of this disorder. Even in specialized laboratories, the precise diagnosis of some fibrinogen disorders may be difficult. Determination of the molecular defects is important because it gives the possibility to confirm the diagnosis, to elaborate a diagnostic strategy, to distinguish in some cases that the patient is at risk of thrombosis rather than bleeding, and to enable prenatal diagnosis. However, genotype–phenotype correlations are not easy to establish. Replacement therapy is effective in treating bleeding episodes, but because the pharmacokinetics of fibrinogen after replacement therapy is highly variable among patients, it is important to adjust the treatment individually.

Keywords

bleeding disorder - fibrinogen - afibrinogenemia - dysfibrinogenemia - hypofibrinogenemia - thrombosis
 

  • References

  • 1 Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218 (5137) 134-137
    CrossrefPubMedGoogle Scholar
  • 2 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103 (2) 215-218
    CrossrefPubMedGoogle Scholar
  • 3 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35 (4) 356-366
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman M, Beutler E, , et al, eds. Williams Hematology. 8th ed. New York, NY: McGraw-Hil; 2010: 1-33
    Google Scholar
  • 5 Galanakis D. Afibrinogenemias and dysfibrinogenemias. In: Marder V, White GC, Aird WC, , eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012: 693-708
    Google Scholar
  • 6 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (8) 1894-1904
    CrossrefPubMedGoogle Scholar
  • 7 Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109 (5) 1971-1974
    CrossrefPubMedGoogle Scholar
  • 8 Medved L, Weisel JW. Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 7 (2) 355-359
    CrossrefPubMedGoogle Scholar
  • 9 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82 (8) 2344-2348
    CrossrefPubMedGoogle Scholar
  • 10 de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12 (5) 377-383
    CrossrefPubMedGoogle Scholar
  • 11 Huang S, Mulvihill ER, Farrell DH, Chung DW, Davie EW. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem 1993; 268 (12) 8919-8926
    PubMedGoogle Scholar
  • 12 Henschen-Edman AH. On the identification of beneficial and detrimental molecular forms of fibrinogen. Haemostasis 1999; 29 (2-3) 179-186
    PubMedGoogle Scholar
  • 13 Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972; 22 (6) 681-700
    CrossrefPubMedGoogle Scholar
  • 14 Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 1993; 82 (1) 135-138
    CrossrefPubMedGoogle Scholar
  • 15 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30
    PubMedGoogle Scholar
  • 16 Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299
    PubMedGoogle Scholar
  • 17 Fenton II JW, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27 (18) 7106-7112
    CrossrefPubMedGoogle Scholar
  • 18 Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost 2007; 98 (1) 105-108
    PubMedGoogle Scholar
  • 19 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106 (13) 4176-4183
    CrossrefPubMedGoogle Scholar
  • 20 Rabe F, Salomon E. Über Faserstoffmangel im Blute bei einem Falle von Hämophilie. Dtsch Arch Klin Med 1920; 132: 240-244
    PubMedGoogle Scholar
  • 21 World Federation of Hemophilia. Report on the Annual Global Survey 2010. Montreal, Quebec, Canada: World Federation of Hemophilia. 2010 1–45. Available at: http://www1.wfh.org/publications/files/pdf-1427.pdf . Accessed June 27, 2013.
    Google Scholar
  • 22 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107 (1) 204-206
    CrossrefPubMedGoogle Scholar
  • 23 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82 (4) 1207-1214
    PubMedGoogle Scholar
  • 24 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (5) 1243-1252
    CrossrefPubMedGoogle Scholar
  • 25 Viswabandya A, Baidya S, Nair SC , et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia 2012; 18 (3) e195-e200
    CrossrefPubMedGoogle Scholar
  • 26 Santacroce R, Cappucci F, Pisanelli D , et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis 2006; 17 (4) 235-240
    CrossrefPubMedGoogle Scholar
  • 27 Acharya SS, Coughlin A, Dimichele DM. North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (2) 248-256
    CrossrefPubMedGoogle Scholar
  • 28 Takezawa Y, Terasawa F, Matsuda K , et al. Molecular analysis of afibrinogenemic mutations caused by a homozygous FGA1238 bp deletion, and a compound heterozygous FGA1238 bp deletion and novel FGA c.54+3A>C substitution. Int J Hematol 2012; 96 (1) 39-46
    CrossrefPubMedGoogle Scholar
  • 29 Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4 (7) 1634-1637
    CrossrefPubMedGoogle Scholar
  • 30 Akcakus M, Patiroglu T, Keskin M, Koklu E, Gozukucuk A. Nonketotic hyperosmolar coma associated with splenic rupture in congenital afibrinogenemia. J Pediatr Hematol Oncol 2004; 26 (10) 668-671
    CrossrefPubMedGoogle Scholar
  • 31 Peyvandi F, Kaufman RJ, Seligsohn U , et al. Rare bleeding disorders. Haemophilia 2006; 12 (Suppl. 03) 137-142
    PubMedGoogle Scholar
  • 32 Aubrey-Bassler FK, Sowers N. 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review. BMC Emerg Med 2012; 12 (1) 11
    CrossrefPubMedGoogle Scholar
  • 33 Rodriguez-Merchan EC. Surgical wound healing in bleeding disorders. Haemophilia 2012; 18 (4) 487-490
    CrossrefPubMedGoogle Scholar
  • 34 James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11 (4) 295-307
    CrossrefPubMedGoogle Scholar
  • 35 Peyvandi F, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. Semin Fetal Neonatal Med 2011; 16 (6) 311-317
    CrossrefPubMedGoogle Scholar
  • 36 Cetinkaya SE, Pabuccu EG, Ozmen B, Dokmeci F. Recurrent massive hemoperitoneum due to ovulation as a clinical sign in congenital afibrinogenemia. Acta Obstet Gynecol Scand 2011; 90 (2) 192-194
    CrossrefPubMedGoogle Scholar
  • 37 Levrat E, Aboukhamis I, de Moerloose P , et al. A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family. Blood Coagul Fibrinolysis 2011; 22 (2) 148-150
    CrossrefPubMedGoogle Scholar
  • 38 Suh TT, Holmbäck K, Jensen NJ , et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9 (16) 2020-2033
    CrossrefPubMedGoogle Scholar
  • 39 Iwaki T, Sandoval-Cooper MJ, Paiva M, Kobayashi T, Ploplis VA, Castellino FJ. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol 2002; 160 (3) 1021-1034
    CrossrefPubMedGoogle Scholar
  • 40 de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 2010; 36 (1) 7-17
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Grandone E, Tiscia G, Cappucci F , et al. Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia 2012; 18 (1) e16-e18
    CrossrefPubMedGoogle Scholar
  • 42 Chevalier Y, Dargaud Y, Argaud L, Ninet J, Jouanneau E, Négrier C. Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report. Thromb Res 2011; 128 (3) 296-298
    CrossrefPubMedGoogle Scholar
  • 43 Ruiz-Sáez A. Thrombosis in rare bleeding disorders. Hematology 2012; 17 (Suppl. 01) S156-S158
    PubMedGoogle Scholar
  • 44 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77 (4) 1272-1277
    CrossrefPubMedGoogle Scholar
  • 45 Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig 1994; 72 (5) 396-398
    CrossrefPubMedGoogle Scholar
  • 46 de Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88 (2) 253-258
    PubMedGoogle Scholar
  • 47 Mosesson MW, Antithrombin I. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89 (1) 9-12
    PubMedGoogle Scholar
  • 48 Ni H, Denis CV, Subbarao S , et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106 (3) 385-392
    CrossrefPubMedGoogle Scholar
  • 49 Remijn JA, Wu YP, Ijsseldijk MJ, Zwaginga JJ, Sixma JJ, de Groot PG. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost 2001; 85 (4) 736-742
    PubMedGoogle Scholar
  • 50 Risak E. Die fibrinogenie. Z Klin Med 1935; 128: 605
    PubMedGoogle Scholar
  • 51 Peyvandi F, Palla R, Menegatti M , et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (4) 615-621
    CrossrefPubMedGoogle Scholar
  • 52 Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109 (2) 364-366
    CrossrefPubMedGoogle Scholar
  • 53 Hill MB, Brennan SO, Dear A, Strong J, Nejim T, Dolan G. Fibrinogen Nottingham II: a novel Bbeta Arg264gly substitution causing hypofibrinogenaemia. Thromb Haemost 2006; 96 (3) 378-380
    PubMedGoogle Scholar
  • 54 Dib N, Quelin F, Ternisien C , et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost 2007; 5 (10) 1999-2005
    CrossrefPubMedGoogle Scholar
  • 55 Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int 2010; 30 (10) 1541-1547
    CrossrefPubMedGoogle Scholar
  • 56 Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen gamma375 Arg—>Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36 (3) 652-658
    CrossrefPubMedGoogle Scholar
  • 57 Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly—>Arg mutation. Am J Pathol 2000; 157 (1) 189-196
    CrossrefPubMedGoogle Scholar
  • 58 Imperato C, Dettori AG. [Congenital hypofibrinogenemia with fibrinoasthenia]. Helv Paediatr Acta 1958; 13 (4) 380-399
    PubMedGoogle Scholar
  • 59 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73 (1) 151-161
    PubMedGoogle Scholar
  • 60 Morris TA, Marsh JJ, Chiles PG , et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114 (9) 1929-1936
    CrossrefPubMedGoogle Scholar
  • 61 Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126 (11) 1387-1390
    PubMedGoogle Scholar
  • 62 Gillmore JD, Lachmann HJ, Rowczenio D , et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009; 20 (2) 444-451
    CrossrefPubMedGoogle Scholar
  • 63 Tavares I, Lobato L, Moreira L , et al. Long-term follow-up of patients with hereditary fibrinogen A alpha-chain amyloidosis. Amyloid 2011; 18 (Suppl. 01) 221-222
    CrossrefPubMedGoogle Scholar
  • 64 Pinney JH, Lachmann HJ, Sattianayagam PT , et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13 (2) 433-441
    CrossrefPubMedGoogle Scholar
  • 65 Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010; 21 (1) 35-40
    CrossrefPubMedGoogle Scholar
  • 66 Dupuy E, Soria C, Molho P , et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102 (3) 211-219
    CrossrefPubMedGoogle Scholar
  • 67 Colvin RB, Mosesson MW, Dvorak HF. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest 1979; 63 (6) 1302-1306
    CrossrefPubMedGoogle Scholar
  • 68 Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114 (2) 249-257
    CrossrefPubMedGoogle Scholar
  • 69 Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126 (6) e428-e433
    CrossrefPubMedGoogle Scholar
  • 70 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 (Suppl. 01) 125-131
    CrossrefPubMedGoogle Scholar
  • 71 Tirefort Y, Alson OR, de Moerloose P, Neerman-Arbez M. Mutation of the translation initiation codon in FGA causes congenital afibrinogenemia. Blood Coagul Fibrinolysis 2012; 23 (6) 556-558
    CrossrefPubMedGoogle Scholar
  • 72 Galanakis DK, Neerman-Arbez M, Scheiner T , et al. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release. Blood Coagul Fibrinolysis 2007; 18 (8) 731-737
    CrossrefPubMedGoogle Scholar
  • 73 Abdel Wahab M, de Moerloose P, Fish RJ, Neerman-Arbez M. Identification and functional characterization of a novel nonsense mutation in FGA accounting for congenital afibrinogenemia in six Egyptian patients. Blood Coagul Fibrinolysis 2010; 21 (2) 164-167
    CrossrefPubMedGoogle Scholar
  • 74 Robert-Ebadi H, de Moerloose P, El Khorassani M, El Khattab M, Neerman-Arbez M. A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream. Blood Coagul Fibrinolysis 2009; 20 (5) 385-387
    CrossrefPubMedGoogle Scholar
  • 75 Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90
    PubMedGoogle Scholar
  • 76 Vorjohann S, Fish RJ, Biron-Andréani C , et al. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'. Thromb Haemost 2010; 104 (5) 990-997
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 77 Lefebvre P, Velasco PT, Dear A , et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103 (7) 2571-2576
    CrossrefPubMedGoogle Scholar
  • 78 Jayo A, Arnold E, González-Manchón C, Green D, Lord ST. Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AalphaIVS4+1G>T mutation and Aalpha4841delC truncation (Aalpha(Perth)). Thromb Haemost 2009; 101 (4) 770-772
    PubMedGoogle Scholar
  • 79 Meyer M, Dietzel H, Kaetzel R, Schmidt D, Liebscher K, Brennan SO. Fibrinogen Leipzig II (gamma351Gly—>Ser and gamma82Ala—>Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain. Thromb Haemost 2007; 98 (4) 903-905
    PubMedGoogle Scholar
  • 80 Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98 (3) 632-639
    CrossrefPubMedGoogle Scholar
  • 81 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA—>stop TAA). Blood 1992; 80 (8) 1972-1979
    PubMedGoogle Scholar
  • 82 Ding Q, Ouyang Q, Xi X, Wang X, Shen Y, Wang H. Maternal chromosome 4 heterodisomy/isodisomy and Bβ chain Trp323X mutation resulting in severe hypodysfibrinogenaemia. Thromb Haemost 2012; 108 (4) 654-661
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 83 Mc Donagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman RW, Hirsh J, Marder V, Clowes A, George J, , eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 855-892
    Google Scholar
  • 84 Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11 (3) 293-304
    PubMedGoogle Scholar
  • 85 Travlou A, Gialeraki A, Merkouri E, Politou M, Sfyridaki A, Neerman-Arbez M. Coexisting dysfibrinogenemia (gamma Arg275His) and FV Leiden associated with thrombosis (Fibrinogen Crete). Thromb Res 2010; 126 (2) e162-e164
    CrossrefPubMedGoogle Scholar
  • 86 Barrowcliffe TW, Cattaneo M, Podda GM , et al. New approaches for measuring coagulation. Haemophilia 2006; 12 (Suppl. 03) 76-81
    CrossrefPubMedGoogle Scholar
  • 87 Kalina U, Stöhr HA, Bickhard H , et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis 2008; 19 (8) 777-783
    CrossrefPubMedGoogle Scholar
  • 88 Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood 2003; 101 (9) 3492-3494
    CrossrefPubMedGoogle Scholar
  • 89 de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther 2008; 8 (7) 979-992
    CrossrefPubMedGoogle Scholar
  • 90 Bolton-Maggs PH, Perry DJ, Chalmers EA , et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (5) 593-628
    CrossrefPubMedGoogle Scholar
  • 91 De Vries A, Rosenberg T, Kochwa S, Boss JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med 1961; 30: 486-494
    CrossrefPubMedGoogle Scholar
  • 92 Ra'anani P, Levi Y, Varon D, Gitel S, Martinowitz U. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen]. Harefuah 1991; 121 (9) 291-293
    PubMedGoogle Scholar
  • 93 Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9 (9) 1687-1704
    CrossrefPubMedGoogle Scholar
  • 94 Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost 2004; 91 (5) 1044-1046
    PubMedGoogle Scholar
  • 95 Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78 (4) 571-572
    CrossrefPubMedGoogle Scholar
  • 96 Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17 (Suppl. 01) 20-30
    CrossrefPubMedGoogle Scholar